Skip to main content

Table 2 Demographic and clinical characteristics of individuals with metastatic melanoma

From: Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data

  Total (N = 12,028) Without autoimmune conditions (n = 9048) With autoimmune conditions (n = 2980) P-value
Age, mean (SD)a 64.2 (14.2) 63.9 (14.4) 65.2 (13.6) < 0.0001
Age group, n (%)a     < 0.0001
 18–34 289 (2.4) 235 (2.6) 54 (1.8)  
 35–54 2614 (21.7) 2049 (22.7) 565 (19.0)  
 55–64 3553 (29.5) 2651 (29.3) 902 (30.3)  
 65–74 2304 (19.2) 1681 (18.6) 623 (20.9)  
  ≥ 75 3268 (27.2) 2432 (26.9) 836 (28.1)  
Gender, n (%)a     < 0.0001
 Male 7574 (63.0) 5824 (64.4) 1750 (58.7)  
 Female 4454 (37.0) 3224 (35.6) 1230 (41.3)  
Health insurance plan, n (%)a    0.042
 Comprehensive 2799 (23.3) 2109 (23.3) 690 (23.2)  
 HMO 1429 (11.9) 1120 (12.4) 309 (10.4)  
 POS 578 (4.8) 438 (4.8) 140 (4.7)  
 PPO 6058 (50.4) 4520 (50.0) 1538 (51.6)  
 Others 1164 (9.7) 861 (9.5) 303 (10.2)  
Medicare beneficiaries, n (%)a    0.007
 Yes 5517 (45.9) 4086 (45.2) 1431 (48.0)  
 No 6511 (54.1) 4962 (54.8) 1549 (52.0)  
Regions, n (%)     0.109
 North East 1760 (14.6) 1296 (14.3) 464 (15.6)  
 North Central 3065 (25.5) 2320 (25.6) 745 (25.0)  
 South 4165 (34.6) 3180 (35.2) 985 (33.1)  
 West 2549 (21.2) 1888 (20.9) 661 (22.2)  
 Unknown/Other 489 (4.1) 364 (4.0) 125 (4.2)  
Metastasis site, n (%)a    < 0.0001
 Brain 2082 (17.3) 1551 (17.1) 531 (17.8)  
 Bone 1541 (12.8) 1044 (11.5) 497 (16.7)  
 Liver 1109 (9.2) 814 (9.0) 295 (9.9)  
 Gastro-intestinal system 386 (3.2) 269 (3.0) 117 (3.9)  
 Lungs 1372 (11.4) 1042(11.5) 330 (11.1)  
Charlson comorbidity score, mean (SD)a   < 0.0001
  0.6 (1.0) 0.5 (0.9) 0.9 (1.3)  
Charlson Category, N (%)a    < 0.0001
 0 8038 (66.8) 6477 (71.6) 1561 (52.4)  
 1 2430 (20.2) 1687 (18.7) 743 (24.9)  
  ≥ 2 1560 (13.0) 884 (9.8) 676 (22.7)  
  1. HMO health maintenance organization, POS point of service plan, PPO preferred provider organization, SD standard deviation
  2. aindicates statistically significant at 5%